Dairy and Non-Dairy Alternatives Comparative on Metabolic Outcomes

Sponsor
University of Toronto (Other)
Overall Status
Completed
CT.gov ID
NCT05919667
Collaborator
(none)
16
1
5
13
1.2

Study Details

Study Description

Brief Summary

The purpose of this study is to compare the acute effects of a single serving of dairy and non-dairy alternatives on post-treatment and post-meal glycemia, appetite, plasma amino acid concentrations, and gastrointestinal hormones levels.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Dairy and plant-based dairy beverages and solids
N/A

Detailed Description

In the past forty years, the prevalence of obesity in adults has doubled with nearly two thirds of Canadian adults currently overweight or obese. The global epidemic of obesity also makes certain individuals more vulnerable to common co-morbidities of obesity, such as type-2-diabetes. To combat these rising numbers, Health Canada released a new Canadian Food Guide (CFG) in 2019. One particular alteration to the new CFG includes dietary guidelines encouraging for an increased consumption of plant-based foods as protein rich sources, shifting away from the promotion of animal-based food products, such as dairy. However, many of the available plant-based substitutes in the market are highly processed with high amounts of sugar, fat, sodium, and additives compared to animal-based products. While literature has shown for plant-based foods to confer numerous health benefits, these are often plant-based foods that have been unprocessed, except for cooking. As the demand for plant-based products continues to grow annually, it is important to assess and compare various obesity and T2D related metabolic outcomes, such as glycemic regulation and appetite control, to better understand the physiological functionality of these products and what role they may or may not play in mitigating the obesity and T2D global epidemics. There is a growing body of evidence from clinical and meta-analysis trials that show dairy products reduce satiety and provide better glycemic control; highlighting their potential to help reduce risk factors associated with obesity and T2D. However, literature has mainly focused on nutrient profile or isolated protein comparatives between animal and plant-based sources. Instead, this study will be looking at comparing dairy products and their plant-based counterparts with respect to their food matrix as a whole, to understand what responses these products produce in the form consumers are naturally eating them by. This study will focus on assessing the metabolic outcomes related to satiety and glycemic regulation. Satiety is an important physiological function related to food intake, and thus, provides a measure to assess reduced obesity risk. Additionally, postprandial glycemic control is an important physiological function that is not only related to the development of type-2 diabetes but also satiety.

A total of 16 participants (8 males and 8 females) will participate in this study at the University of Toronto.

The study will include a total of 5 sessions over the span of 5 weeks. Prior to the visit, participants will be fasted for 12 hours, excluding water for up to 1 hour before the study visit. During each session, participants will consume a dairy product or a non-dairy plant-based product while subjective appetite, blood glucose, insulin, C-peptide, and gut hormones (ghrelin, GLP-1, GLP-2, and GIP) are obtained post-treatment at 20 min and post a secondary fixed meal of pasta within 15-30 min intervals over a 2 hour timespan. Plasma amino acid concentrations will also be measured within the same timeline outlined above.

Study Design

Study Type:
Interventional
Actual Enrollment :
16 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Single (Participant)
Masking Description:
Randomized, single-blinded
Primary Purpose:
Basic Science
Official Title:
The Effects of Dairy and Non-Dairy Alternatives on Glycemic and Appetite Regulation in Healthy Young Adults
Actual Study Start Date :
Feb 28, 2022
Actual Primary Completion Date :
Feb 28, 2022
Actual Study Completion Date :
Mar 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Dairy-based Product 1

2% Cow's milk (Neilson, St-Laurent, Quebec)

Dietary Supplement: Dairy and plant-based dairy beverages and solids
Crossover design: participants received all treatment arms in a randomized order

Experimental: Dairy-based Product 2

Regular fat cheddar cheese (Armstrong, St-Laurent, Québec)

Dietary Supplement: Dairy and plant-based dairy beverages and solids
Crossover design: participants received all treatment arms in a randomized order

Experimental: Plant-based Product 3:

Vanilla Soy Beverage (Silk, Broomfield, Colorado)

Dietary Supplement: Dairy and plant-based dairy beverages and solids
Crossover design: participants received all treatment arms in a randomized order

Experimental: Plant-based Product 4

Vanilla Almond Beverage (Earth's Own, Vancouver, British Columbia)

Dietary Supplement: Dairy and plant-based dairy beverages and solids
Crossover design: participants received all treatment arms in a randomized order

Experimental: Plant-based Product 5

Plant-based Cheddar-Style Block (President' Choice, Brampton, Ontario)

Dietary Supplement: Dairy and plant-based dairy beverages and solids
Crossover design: participants received all treatment arms in a randomized order

Outcome Measures

Primary Outcome Measures

  1. Change in blood glucose level [Starting at the beginning of each sessions (0 min, before consumption of treatment) and every 15-30 minutes up to 160 minutes]. A total of 9 times.]

    Venous blood collection via catheter

Secondary Outcome Measures

  1. Subjective appetite [Measured every 15-30 minutes up to 160 minutes]. A total of 9 times.]

    Quantifying appetite by using Visual Analogue Scales. Scored 0 to 100 How strong is your desire to eat? How hungry do you feel? How full do you feel? How much food do you think you could eat?

  2. Change in plasma metabolic and gut hormones (insulin, c-peptide, glucagon-like 1 receptor, glucagon-like 2 peptide and gastric inhibitory polypeptide) [Starting at the beginning of each session (0 minutes, before consumption of treatment) and every 15-30 minutes up to 160 minutes]. A total of 7 times.]

    Venous blood collection via catheter

  3. Change in plasma amino acid concentrations [Starting at the beginning of each session (0 minutes, before consumption of treatment) and every 15-30 minutes up to 160 minutes]. A total of 7 times.]

    Venous blood collection via catheter

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 30 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • BMI: ≥18.5 kg/m2 and ≤ 24.5 kg/m2'

  • Fasting serum glucose: ≤ 5.5 mmol/L

  • Frequent breakfast consumers

  • Willing to maintain habitual diet, physical activity pattern, dietary supplement routine, and body weight throughout the trial

  • Willing to abstain from alcohol consumption for 24 h prior to all test visits.

  • Willing to avoid vigorous physical activity for 24 h prior to all test visits.

  • Understanding the study procedures and willing to provide informed consent to participate in the study and authorization to release relevant protected health information to the study investigator.

Exclusion Criteria:
  • Fasting blood glucose > 5.5 mmol/L

  • Smoking tobacco products and marijuana regularly

  • Previous history of cardiovascular disease, diabetes, liver or kidney disease, inflammatory bowel disease, celiac disease, short bowel syndrome, any malabsorptive syndrome, pancreatitis, gallbladder or biliary disease

  • Presence of gastrointestinal disorder or surgeries within the past year

  • Consuming prescription or non-prescription drug, herbal or nutritional supplements known to affect blood glucose, appetite and/or any other outcomes of the study as per investigator's judgment

  • Known to be pregnant or lactating, or planning on becoming pregnant in the next 12 months

  • Irregular menstrual cycles (i.e., frequent missed cycles), menopausal or post- menopausal

  • Breakfast skippers

  • Currently trying to lose or gain weight and any weight gain or loss of at least 10 lbs in previous three months

  • Known intolerance, sensitivity or allergy to dairy products (including milk and cheese)

  • Consumption of powders/protein supplements

  • Extreme dietary habits

  • Excessive alcohol intake

  • Restrained Eaters

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Nutritional Sciences, C. David Naylor Building Toronto Ontario Canada M5S 3H2

Sponsors and Collaborators

  • University of Toronto

Investigators

  • Principal Investigator: G. Harvey Anderson, PhD, University of Toronto

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
G. Harvey Anderson, Professor, University of Toronto
ClinicalTrials.gov Identifier:
NCT05919667
Other Study ID Numbers:
  • MYC_AcuteDairy_2022
First Posted:
Jun 26, 2023
Last Update Posted:
Jun 26, 2023
Last Verified:
Jun 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by G. Harvey Anderson, Professor, University of Toronto
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 26, 2023